Literature DB >> 2871852

The haemodynamic and myocardial effects of dopexamine: a new beta 2-adrenoceptor and dopaminergic agonist.

B E Jaski, W Wijns, R Foulds, P W Serruys.   

Abstract

Dopexamine increases inotropic state and rate of relaxation independent of changes in heart rate. Dopexamine has a chronotropic effect and results in a decrease in systemic vascular resistance. Dopexamine has a spectrum of action that should be useful in patients with severe heart failure.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2871852      PMCID： PMC1400939          DOI： 10.1111/j.1365-2125.1986.tb05213.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  21 in total

Review 1.  Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine.

Authors:  L I Goldberg; Y Y Hsieh; L Resnekov
Journal:  Prog Cardiovasc Dis       Date:  1977 Jan-Feb       Impact factor: 8.194

Review 2.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

3.  A computer system for real time analysis of cardiac catheterization data.

Authors:  G T Meester; N Bernard; C Zeelenberg; R W Brower; P G Hugenholtz
Journal:  Cathet Cardiovasc Diagn       Date:  1975

4.  Pharmacologic and hemodynamic influences on the rate of isovolumic left ventricular relaxation in the normal conscious dog.

Authors:  J S Karliner; M M LeWinter; F Mahler; R Engler; R A O'Rourke
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

5.  Hemodynamic determinants of the time-course of fall in canine left ventricular pressure.

Authors:  J L Weiss; J W Frederiksen; M L Weisfeldt
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

Review 6.  Cardiovascular and renal actions of dopamine: potential clinical applications.

Authors:  L I Goldberg
Journal:  Pharmacol Rev       Date:  1972-03       Impact factor: 25.468

7.  Beta-adrenoceptors of the human myocardium: determination of beta 1 and beta 2 subtypes by radioligand binding.

Authors:  A Heitz; J Schwartz; J Velly
Journal:  Br J Pharmacol       Date:  1983-12       Impact factor: 8.739

8.  Beneficial effect of salbutamol on cardiac function in severe congestive cardiomyopathy. Effect on systolic and diastolic function of the left ventricle.

Authors:  B Sharma; J F Goodwin
Journal:  Circulation       Date:  1978-09       Impact factor: 29.690

9.  Influence of acute changes in preload, afterload, contractile state and heart rate on ejection and isovolumic indices of myocardial contractility in man.

Authors:  M A Quinones; W H Gaasch; J K Alexander
Journal:  Circulation       Date:  1976-02       Impact factor: 29.690

10.  pA2 values of selective beta-adrenoceptor antagonists on isolated atria demonstrate a species difference in the beta-adrenoceptor populations mediating chronotropic responses in cat and guinea-pig.

Authors:  S R O'Donnell; J C Wanstall
Journal:  J Pharm Pharmacol       Date:  1979-10       Impact factor: 3.765
View more
  9 in total

1.  Failure of dopexamine to maintain haemodynamic improvement in patients with chronic heart failure.

Authors:  J J Murphy; J R Hampton
Journal:  Br Heart J       Date:  1988-07

Review 2.  Dopexamine in congestive heart failure: how do the pharmacological activities translate into the clinical situation?

Authors:  T Meinertz; H Drexler; H Just
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

3.  Comparison of the effects of dopamine, dobutamine, and dopexamine upon renal blood flow: a study in normal healthy volunteers.

Authors:  S Mousdale; P A Clyburn; A M Mackie; N D Groves; M Rosen
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

4.  The effects of dopexamine, a new dopamine analogue, on platelet function in stress.

Authors:  D Wagaine-Twabwe; T J Hendra; C C Smith; J S Yudkin
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

5.  Circulatory and diuretic effects of dopexamine infusion in low-birth-weight infants with respiratory failure.

Authors:  P Kawczynski; A Piotrowski
Journal:  Intensive Care Med       Date:  1996-01       Impact factor: 17.440

6.  Studies on the pharmacological interventions to prevent oxygen free radical (OFR)-mediated toxicity; effects of dopexamine, a DA1 receptor and beta 2 adrenoceptor agonist.

Authors:  S M Jacinto; M F Lokhandwala; B S Jandhyala
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-09       Impact factor: 3.000

7.  Inhibition of Uptake1 by dopexamine hydrochloride in vitro.

Authors:  P D Mitchell; G W Smith; E Wells; P A West
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

8.  Haemodynamic response to dopexamine hydrochloride in postinfarction heart failure: lack of tolerance after continuous infusion.

Authors:  G Svenson; L E Strandberg; B Lindvall; L Erhardt
Journal:  Br Heart J       Date:  1988-12

Review 9.  Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency.

Authors:  A Fitton; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.